Financials Celltrion, Inc.

Equities

A068270

KR7068270008

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 2024-12-13			5-day change	1st Jan Change
193,400.00 ^KRW	+4.60%		+6.85%	-4.02%

Dec. 10	South Korean Shares Rebound on Market Stabilization Optimism; Celltrion Gains 4% on Asthma Drug's Canada Approval	MT
Dec. 10	Health Canada Approves Celltrion's Asthma Biosimilar Omlyclo; Shares Rise 3%	MT

Projected Income Statement: Celltrion, Inc.

income-statement-evolution-chart CELLTRION-INC

Fiscal Period: Dezember	2019	2020	2021	2022	2023	2024	2025	2026
Net sales ¹	1,128	1,849	1,891	2,284	2,176	3,485	4,408	5,347
Change	-	63.86%	2.26%	20.79%	-4.71%	60.12%	26.49%	21.29%
EBITDA ¹	537.3	891.4	972.1	873.6	897.2	972.1	1,856	2,450
Change	-	65.91%	9.06%	-10.14%	2.7%	8.36%	90.89%	32.02%
EBIT ¹	378.1	712.1	753.9	647.2	651.5	577.5	1,516	2,105
Change	-	88.36%	5.86%	-14.15%	0.66%	-11.36%	162.47%	38.88%
Interest Paid ²	-10,828	-7,503	-8,238	-7,508	-9,665	-59,000	-39,286	-39,429
Earnings before Tax (EBT) ¹	378.6	650.7	746.9	626.2	671.1	600.5	1,570	2,151
Change	-	71.88%	14.79%	-16.17%	7.17%	-10.52%	161.52%	36.99%
Net income ¹	297.6	511.3	575.1	533.2	535.6	461.5	1,213	1,644
Change	-	71.81%	12.48%	-7.29%	0.47%	-13.84%	162.85%	35.5%
Announcement Date	2/19/20	2/22/21	2/16/22	3/3/23	2/29/24	-	-	-

¹KRW in Billions²KRW in Million

Estimates

Fiscal Period: December	2019 Q4	2020 Q1	2020 Q2	2020 Q3	2020 Q4	2021 Q1	2021 Q2	2021 Q3	2021 Q4	2022 Q1	2022 Q2	2022 Q3	2022 Q4	2023 Q1	2023 Q2	2023 Q3	2023 Q4	2024 Q1	2024 Q2	2024 Q3	2024 Q4	2025 Q1	2025 Q2	2025 Q3	2025 Q4	2026 Q1	2026 Q2	2026 Q3
Net sales ¹	382.7	372.8	428.8	548.8	498.7	457	431.8	401	601.1	550.6	596.1	645.6	510.6	597.5	524	672.3	382.6	737	874.7	881.9	1,005	989.1	1,083	1,171	1,266	1,405	1,612	1,758
Change	-	-2.58%	15.01%	27.98%	-9.12%	-8.37%	-5.51%	-7.14%	49.92%	-8.41%	8.26%	8.32%	-20.91%	17.01%	-12.3%	28.31%	-43.09%	92.63%	18.69%	0.82%	14.01%	-1.63%	9.54%	8.06%	8.17%	10.95%	14.75%	9%
EBITDA ¹	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	147	204.7	283.4	284.3	390.4	453.9	475.4	496	-	-	-
Change	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	39.21%	38.42%	0.33%	37.32%	16.27%	4.75%	4.32%	-100%	-	-
EBIT ¹	114.2	120.2	181.8	245.3	164.7	207.7	163.2	164	219	142.3	199	213.8	100.6	182.4	183	267.6	18.42	15.44	72.49	207.7	282.4	286.5	340.5	408.5	482.8	533.2	629.7	687.9
Change	-	5.3%	51.23%	34.88%	-32.83%	26.04%	-21.4%	0.47%	33.57%	-35.04%	39.84%	7.44%	-52.93%	81.22%	0.35%	46.25%	-93.12%	-16.21%	369.57%	186.51%	35.96%	1.47%	18.84%	19.97%	18.2%	10.44%	18.1%	9.24%
Charge d'intérêts	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Earnings before Tax (EBT) ¹	104.7	138.4	180.6	231	100.7	258.4	155.6	187.6	145.2	-	226.8	217.3	48.49	208.2	189.7	282.9	-	-	104.2	178.2	316	-	-	-	-	-	-	-
Change	-	32.27%	30.45%	27.9%	-56.41%	156.69%	-39.79%	20.57%	-22.6%	-100%	-	-4.18%	-77.69%	329.38%	-8.89%	49.12%	-100%	-	-	71.07%	77.28%	-100%	-	-	-	-	-	-
Net income ¹	95.03	104.9	138.1	170.7	97.57	-	125.5	135.5	120.5	118.5	183.4	166.7	64.53	166.9	147.5	221.8	1.054	22.44	78.01	85.59	243.8	241.8	282.4	238.2	479	-	-	-
Change	-	10.42%	31.59%	23.6%	-42.83%	-100%	-	7.96%	-11.08%	-1.62%	54.75%	-9.12%	-61.29%	158.61%	-11.61%	50.38%	-99.52%	2,028.84%	247.68%	9.72%	184.84%	-0.81%	16.77%	-15.66%	101.12%	-100%	-	-
Announcement Date	2/19/20	5/8/20	8/7/20	11/9/20	2/22/21	5/12/21	8/13/21	11/10/21	2/16/22	5/12/22	8/5/22	11/9/22	3/3/23	5/8/23	8/14/23	11/7/23	2/29/24	5/9/24	8/7/24	11/8/24	-	-	-	-	-	-	-	-

¹KRW in Billions

Estimates

Forecast Balance Sheet: Celltrion, Inc.

balance-sheet-analysis-chart CELLTRION-INC

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Net Debt ¹	-128	100	-476	236	1,310	1,088	895	369
Change	-	-21.88%	-576%	-50.42%	455.08%	-16.92%	-17.74%	-58.77%
Announcement Date	2/19/20	2/22/21	2/16/22	3/3/23	2/29/24	-	-	-

¹KRW in Billions

Estimates

Cash Flow Forecast: Celltrion, Inc.

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
CAPEX ¹	94.28	87.01	63.38	111.2	210	159	143.1	160.4
Change	-	-7.71%	-27.16%	75.4%	88.94%	-24.29%	-9.99%	12.05%
Free Cash Flow (FCF) ¹	379,716	263,739	589,594	-110,305	327,112	928,100	1,163,190	1,346,036
Change	-	-30.54%	123.55%	-118.71%	-396.55%	183.73%	25.33%	15.72%
Announcement Date	2/19/20	2/22/21	2/16/22	3/3/23	2/29/24	-	-	-

¹KRW in Million

Estimates

Forecast Financial Ratios: Celltrion, Inc.

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Profitability
EBITDA Margin (%)	47.61%	48.21%	51.41%	38.25%	41.22%	27.9%	42.1%	45.82%
EBIT Margin (%)	33.5%	38.51%	39.87%	28.34%	29.93%	16.57%	34.39%	39.37%
EBT Margin (%)	33.55%	35.19%	39.5%	27.42%	30.83%	17.23%	35.63%	40.24%
Net margin (%)	26.37%	27.65%	30.42%	23.34%	24.61%	13.24%	27.52%	30.74%
FCF margin (%)	33,649.04%	14,262.95%	31,181.9%	-4,829.54%	15,029.76%	26,632.58%	26,388.52%	25,175.56%
FCF / Net Income (%)	127,593.57%	51,582.76%	102,521.45%	-20,688.64%	61,068.54%	201,105.21%	95,889.45%	81,888.37%
Profitability
ROA	8.02%	11.61%	10.7%	9.22%	4.31%	2.11%	5.79%	7.2%
ROE	11.21%	16.68%	16.5%	12.93%	5.07%	2.63%	6.88%	8.95%
Financial Health
Leverage (Debt/EBITDA)	-	0.11x	-	0.27x	1.46x	1.12x	0.48x	0.15x
Debt / Free cash flow	-	0x	-	-0x	0x	0x	0x	0x
Capital Intensity
CAPEX / Current Assets (%)	8.35%	4.71%	3.35%	4.87%	9.65%	4.56%	3.25%	3%
CAPEX / EBITDA (%)	17.55%	9.76%	6.52%	12.73%	23.41%	16.36%	7.71%	6.55%
CAPEX / FCF (%)	0.02%	0.03%	0.01%	-0.1%	0.06%	0.02%	0.01%	0.01%
Items per share
Cash flow per share ¹	3,430	2,460	6,417	6.246	3,764	3,820	7,108	9,746
Change	-	-28.27%	160.82%	-99.9%	60,152.19%	1.49%	86.08%	37.13%
Dividend per Share ¹	-	-	721.2	-	500	500	505.6	609.3
Change	-	-	-	-	-	0%	1.11%	20.52%
Book Value Per Share ¹	20,218	23,501	27,732	30,040	81,950	81,341	86,527	94,016
Change	-	16.24%	18%	8.32%	172.8%	-0.74%	6.38%	8.65%
EPS ¹	2,153	3,586	4,031	3,855	3,753	2,113	5,652	7,847
Change	-	66.53%	12.4%	-4.36%	-2.65%	-43.7%	167.51%	38.83%
Nbr of stocks (in thousands)	144,521	144,757	144,931	143,304	138,811	206,152	206,152	206,152
Announcement Date	2/19/20	2/22/21	2/16/22	3/3/23	2/29/24	-	-	-